{
    "2021-12-21": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Aduhelm",
                        "price cut",
                        "Alzheimer's"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-10",
                "original_text": "Eli Lilly's (NYSE:LLY) Shareholders Will Receive A Bigger Dividend Than Last Year",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "dividend",
                        "shareholders"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-05-20",
                "original_text": "Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "lebrikizumab",
                        "Phase 3",
                        "atopic dermatitis",
                        "clinical trial success"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}